Atherogenesis and inflammation - Was Virchow right?

Nephrology Dialysis Transplantation

Volumn 22, Issue 7, 2007, Pages 1823-1827

  Methe, Heiko ^a   Weis, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adaptive immunity; Atherosclerosis; Dendritic cells; Immune system; Innate immunity; Toll like receptors

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN B100; ASCORBIC ACID; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; OXIDIZED LOW DENSITY LIPOPROTEIN; PLATELET DERIVED GROWTH FACTOR; SEVELAMER; STEROID; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; ENDOTHELIUM LESION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; UREMIA; VACCINATION;

ANTIGENS; ATHEROSCLEROSIS; DISEASE PROGRESSION; HISTORY, 19TH CENTURY; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; INFLAMMATION; UREMIA;

EID: 34547830274     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm112     Document Type: Review

References (45)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
3. Mayerl C, Lukasser M, Sedivy R, Niederegger H, Seiler R, Wick G. Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch 2006; 449: 96-103
4. Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006; 203: 2073-2083
5. Getz GS. Thematic review series: The immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res 2005; 46: 1-10
6. Robertson AK, Hansson GK. T cells in atherogenesis: For better or for worse? Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432
7. Methe H, Edelman ER. Cell-matrix contact prevents recognition and damage of endothelial cells in states of heightened immunity. Circulation 2006; 114[1 Suppl]: I233-I238
8. Weis M, von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med 2000; 51: 81-100
9. Quehenberger O. Thematic review series: The immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. J Lipid Res 2005; 46: 1582-1590
10. Weis M, Schlichting CL, Engleman EG, Cooke JP. Endothelial determinants of dendritic cell adhesion and migration. New implications for vascular diseases. Arterioscler Thromb Vasc Biol 2002; 22: 1817-1823
11. Ludewig B, Laman JD. The in and out of monocytes in atherosclerotic plaques: Balancing inflammation through migration. Proc Natl Acad Sci USA 2004; 101: 11529-11530
12. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-11784
13. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: A focus on endothelial responses to inflammation. Clin Sci 2005; 108: 205-213
14. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 2005; 45: 1939-1945
15. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111: 2654-2661
16. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-1226
17. Shah PK, Chyu KY, Fredrikson GN, Nilsson J. Immunomodulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiovasc Med 2005; 2: 639-646
18. Sherer Y, Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract 2006; 2: 99-106
19. Giles JT, Post W, Blumenthal RS, Bathon JM. Therapy Insight: Managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract 2006; 2: 320-329
20. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406
21. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823-835
22. Kawai T, Akira S. Pathogen recognition with toll-like receptors. Curr Opin Immunol 2005; 17: 338-344
23. Michelsen KS, Arditi M. Toll-like receptor signaling and atherosclerosis. Curr Opin Hematol 2006; 13: 163-168
24. Bjorkbacka H. Multiple roles of toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 2006; 17: 527-533
25. Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 416-421
26. Michelsen KS, Wong MH, Shah PK et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces athero- sclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-10684
27. Mullick AE, Tobias PS, Curtiss LK. Modulation of athero- sclerosis in mice by toll-like receptor 2. J Clin Invest 2005; 115: 3149-3156
28. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001; 7: 761-765
29. Bobryshev YV. Dendritic cells in atherosclerosis: Current status of the problem and clinical relevance. Eur Heart J 2005; 26: 1700-1704
30. Millonig G, Niederegger H, Rabl W et al. Network of vascular- associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol 2001; 21: 503-508
31. Yilmaz A, Weber J, Cicha I et al. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J Am Coll Cardiol 2006; 48: 70-80
32. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-{alpha}. Circulation 2006; 114: 2482-2489
33. Kearney JF. Immune recognition of OxLDL in atherosclerosis. J Clin Invest 2000; 105: 1683-1685
34. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: A role for heat shock proteins in immunisation. Atherosclerosis 2003; 167: 177-185
35. Ludewig B, Krebs P, Scandella E. Immunopathogenesis of atherosclerosis. J Leukocyte Biol 2004; 76: 300-306
36. Smieja M, Gnarpe J, Lonn E et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 251-257
37. Petrakopoulou P, Kubrich M, Pehlivanli S et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110 [11 Suppl 1]: II207-II212
38. Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: More important than direct viral effects in cardiovascular disease? J Clin Virol 2006; 35: 349-353
39. Descamps-Latscha B, Jungers P, Witko-Sarsat V. Immune system dysregulation in uremia: Role of oxidative stress. Blood purificat 2002; 20: 481-484
40. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
41. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-362
42. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet. 2003; 361: 827-833
43. Galle J, Seibold S, Wanner C. Inflammation in uremic patients: What is the link? Kidney Blood Press R 2003; 26: 65-75
44. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-2882
45. Ivanovski O, Szumilak D, Nguyen-Khoa T et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005; 67: 2288-2294